協合新能源(00182.HK)2.44億元售兩風電場予中核山東 獲利逾1億元
格隆匯11月27日丨協合新能源(00182.HK)公佈,於2019年11月27日,公司全資附屬永州界牌與中核山東及通道協合訂立股權轉讓協議,永州界牌擬向中核山東出售通道協合100%股權,代價為人民幣2.4438億元。
通道協合主要從事傳素項目及臨口項目的發展及營運。傳素項目於2014年6月5日獲通道侗族自治縣發展和改革局批准。傳素風電場的獲批裝機容量為48MW。臨口項目於2013年10月21日獲湖南省發展和改革委員會批准。臨口風電場的獲批裝機容量為48MW。
董事預期出售事項的所得款項淨額(經扣除相關直接應占開支後)約為人民幣1.0066億元,其將被用作集團的一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.